Abstract:Abstract Urothelial bladder cancer (UBC) affects the epithelial cells of the urinary tract and is the most common type of bladder cancer worldwide. Statistically, males are four times more likely to develop UBC than females. It is known that decreased expression of the KDM6A gene, coded on the X chromosome, corresponds with a higher incidence of UBC. KDM6A mutations are known to be more prevalent in females with non-muscle-invasive UBC. These mutations are targetable by inhibiting EZH2, an enzyme coded by its namesake gene. On the environmental side, males are at a higher risk of developing carcinogenic complications due to smoking and environmental toxins. However, this discrepancy fails to exist when comparing males and females who smoke similar levels. Though environmental factors may play a role in influencing behavior and altering levels of risk to develop UBC, research suggests that they do not single-handedly explain sex-based disparities in UBC. In this study, we characterize the molecular mechanisms associated with altered overall survival by uncovering previously unreported data on the expression of KDM6A and FGFR3, a commonly altered oncogene, in UBC patients. Our in silico approach consisted of broad survival data analysis through cBioPortal (n=1486), sequencing-based gene expression data through ICGC Portal (n=295), and single nucleotide polymorphism identification with the PLCO Atlas (n=69,429). The 5-year overall survival (OS) curves of 13 therapeutic and/or significantly altered genes between males and females were analyzed. BRCA2 was the only gene associated with worse survival for females with alterations. Interestingly, males with alterations to the following genes had significantly better OS outcomes: ERCC2, KDM6A, BRCA2, FGFR3. However, there was no gene whose alterations were associated with significantly better OS outcomes for females. KDM6A and FGFR3, two genes whose alterations are typically associated with worse OS outcomes in males, exhibit the opposite effect. Additionally, males exhibited significantly worse OS outcomes when presenting with CDKN2A and CDKN2B alterations, while females exhibited significantly worse OS outcomes when presenting with CDKN2A and NTRK1. A majority of European males had SNPs on the following genes: CDKN2B, ERBB2, CREBBP, while a majority of European females had SNPs on BRCA2. Differential expression also revealed 714 genes that were significantly expressed in one sex when compared to the other. Therefore, we suggest that there are unique molecular differences between sex that conflict with previous analyses; further research should be conducted to explore the effect of sex via the tumor-suppressive characteristics of KDM6A as well as oncogenic properties of FGFR3. Citation Format: Rishi Nair, Roy Khalife, Anthony Magliocco. Genetic characteristics between males and females with urothelial bladder cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 883.

Y-Linked Lysine(K) Demethylase 5D as a regulator of sex-specific bladder cancer metastasis and prognosis

Histone demethylase KDM5D upregulation drives sex differences in colon cancer

Abstract 3515: Histone demethylase KDM5D drives sex-specific differences in colorectal cancer

Histone H3K36me2 demethylase KDM2A promotes bladder cancer progression through epigenetically silencing RARRES3

Abstract PR011: Histone demethylase KDM5D drives sex-specific differences in colorectal cancer

Gender Disparities in Clinical Outcomes of Urothelial Carcinoma Linked to X Chromosome Genekdm6amutation

KDM5D Inhibit Epithelial-Mesenchymal Transition of Gastric Cancer Through Demethylation in the Promoter of Cul4A in Male

An Integrative Study to Investigate Sex-Specific Biomarkers in Bladder Cancer Patients

Abstract LB259: Cell context-dependent role of KDM5D in ATR and CHK1 inhibitor sensitivity in prostate cancer

Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction

Lysine Demethylase 5A Promotes Prostate Adenocarcinoma Progression by Suppressing Microrna-330-3p Expression and Activating the COPB2/PI3K/AKT Axis in an ETS1-dependent Manner

Methylation-mediated Silencing of Dlg5 Facilitates Bladder Cancer Metastasis.

Analysis of the Role of Mutations in the KMT2D Histone Lysine Methyltransferase in Bladder Cancer

Gender Dimorphism in Survival of Patients with Lymph Node Metastasis of Bladder Cancer

DLGAP5 triggers proliferation and metastasis of bladder cancer by stabilizing E2F1 via USP11

Gene Expression and Regulatory Webwork of POLR2K in Bladder Carcinogenesis by Integrated Bioinformatics Approaches

Abstract 1718: The lysine demethylase KDM2A regulates tumor cell clustering to potentiate metastasis

Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer.

Abstract A012: Kmt2c/d loss primes urothelium for tumorigenesis and redistributes Menin to bivalent promoters

Abstract 883: Genetic characteristics between males and females with urothelial bladder cancer

Enhancing m6A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer